Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X4KN
|
|||
| Former ID |
DNCL002302
|
|||
| Drug Name |
BI-836845
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Boehringer Ingelheim Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Insulin-like growth factor-I (IGF1) | Target Info | Modulator | [2] |
| Pathway Interaction Database | Plasma membrane estrogen receptor signaling | |||
| SHP2 signaling | ||||
| IGF1 pathway | ||||
| Ceramide signaling pathway | ||||
| Integrins in angiogenesis | ||||
| Stabilization and expansion of the E-cadherin adherens junction | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02145741) Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours. U.S. National Institutes of Health. | |||
| REF 2 | Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.Mol Cancer Ther.2014 Feb;13(2):399-409. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.